Differential Diagnosis of Flavivirus Infections in Horses Using Viral Envelope Protein Domain III Antigens in Enzyme-Linked Immunosorbent Assay.

The research article explores the use of the domain III of the envelope (E) protein in flaviviruses such as West Nile Virus (WNV) and Murray Valley Encephalitis Virus (MVEV) as a diagnostic marker for infections in horses. The study shows that these proteins can be used to differentially diagnose between these two infections in horses with a similar level of accuracy to currently used tests.

Study Objectives and Methodology

• The main objective of the study was to explore a different approach to diagnosing infections of the West Nile virus (WNV) and Murray Valley encephalitis virus (MVEV) in horses. The two infections often cause severe neurological diseases that are clinically indistinguishable.
• Confirmatory serological tests, which detect antibodies specific for either MVEV or WNV in horses, are often complicated by cross-reactive antibodies that cling to the conserved epitopes on the envelope (E) protein common to different flaviviruses.
• The researchers utilized recombinant antigens derived from domain III of the E protein (rE-DIII) of both MVEV and WNV. They proposed that these proteins may offer specific diagnostic markers of infection with these two viruses.
• The research involved testing a panel of 130 serum samples from horses with known flavivirus infection statuses using an enzyme-linked immunosorbent assay (ELISA) with the rE-DIII antigens.

Results and Findings

• Based on testing the panel of serum samples, a differential diagnosis of MVEV or WNV was achieved for most samples. This meant that the rE-DIII antigens were effective in differentiating between the two infections in most instances.
• Time-point samples from horses exposed to flavivirus infection during a 2011 outbreak of equine encephalitis in Australia showed that these rE-DIII antigens could detect and differentiate MVEV and WNV infections in convalescent sera.
• The effectiveness of these rE-DIII antigens was similar to that of virus neutralization tests and blocking ELISAs, which are currently used to diagnose these infections. This highlighted the potential use of rE-DIII as a viable diagnostic marker.

Implications and Conclusion

• The findings were significant in that they indicated the feasibility of using rE-DIII as a diagnostic antigen in rapid immunoassays for confirming the presence of MVEV and WNV infections in horses, particularly in the Australian context.
• The researchers hence recommended that these rE-DIII antigens undergo further assessment in sensitive, high-throughput serological platforms, such as multiplex immune assays, to validate their efficacy.